Tema Etfs LLC Sells 5,037 Shares of Masimo Corporation $MASI

Key Points

• Tema Etfs LLC has reduced its stake in Masimo Corporation by 52.6%, now owning 4,543 shares valued at approximately $757,000.
• Masimo reported a quarterly EPS of $1.33, exceeding estimates, with revenue of $370.90 million, a 7.7% increase from the previous year.
• Five research analysts currently maintain a "Buy" rating on Masimo shares, with an average price target of $193.60.

Tema Etfs LLC reduced its holdings in Masimo Corporation (NASDAQ:MASI - Free Report) by 52.6% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,543 shares of the medical equipment provider's stock after selling 5,037 shares during the period. Tema Etfs LLC's holdings in Masimo were worth $757,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in MASI. Farther Finance Advisors LLC grew its stake in shares of Masimo by 128.9% in the 1st quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider's stock worth $35,000 after buying an additional 116 shares in the last quarter. NBC Securities Inc. purchased a new position in shares of Masimo in the 1st quarter worth $61,000. UMB Bank n.a. grew its stake in shares of Masimo by 134.0% in the 1st quarter. UMB Bank n.a. now owns 447 shares of the medical equipment provider's stock worth $74,000 after buying an additional 256 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Masimo by 58.4% in the 1st quarter. GAMMA Investing LLC now owns 738 shares of the medical equipment provider's stock worth $123,000 after buying an additional 272 shares in the last quarter. Finally, Ballentine Partners LLC purchased a new position in shares of Masimo in the 1st quarter worth $206,000. 85.96% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Masimo

In other Masimo news, Director William R. Jellison purchased 3,000 shares of Masimo stock in a transaction dated Monday, August 11th. The stock was acquired at an average price of $145.98 per share, for a total transaction of $437,940.00. Following the acquisition, the director owned 4,790 shares in the company, valued at $699,244.20. This trade represents a 167.60% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 16.90% of the company's stock.

Masimo Trading Down 0.9%

Masimo stock traded down $1.24 during trading hours on Monday, hitting $139.71. The company had a trading volume of 459,927 shares, compared to its average volume of 889,016. The firm has a market cap of $7.59 billion, a P/E ratio of -16.40 and a beta of 1.23. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.61 and a current ratio of 2.14. Masimo Corporation has a 1 year low of $107.98 and a 1 year high of $194.88. The company has a 50-day moving average price of $157.17 and a two-hundred day moving average price of $161.50.

Masimo (NASDAQ:MASI - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The medical equipment provider reported $1.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.11. The company had revenue of $370.90 million during the quarter, compared to analysts' expectations of $368.65 million. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The firm's quarterly revenue was up 7.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.86 EPS. On average, sell-side analysts anticipate that Masimo Corporation will post 4.1 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Wells Fargo & Company dropped their price target on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. BTIG Research reaffirmed a "buy" rating on shares of Masimo in a research note on Thursday, August 14th. Wall Street Zen cut shares of Masimo from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Raymond James Financial dropped their price target on shares of Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Finally, Piper Sandler lifted their price target on shares of Masimo from $200.00 to $210.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Masimo currently has an average rating of "Moderate Buy" and a consensus target price of $193.60.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.